E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Hepatocellular carcinoma |
Carcinoma hepatocelular |
|
E.1.1.1 | Medical condition in easily understood language |
Liver cancer |
Cáncer de hígado |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | SOC |
E.1.2 | Classification code | 10029104 |
E.1.2 | Term | Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this study is to evaluate the efficacy of cabozantinib in combination with atezolizumab versus sorafenib in subjects with advanced HCC who have not received previous systemic anticancer therapy. An exploratory objective is to evaluate the single-agent activity of cabozantinib in this patient population. |
El objetivo principal de este estudio es evaluar la eficacia de cabozantinib combinado con atezolizumab frente a sorafenib en pacientes con CHC avanzado que no han recibido ningún tratamiento antineoplásico sistémico anterior. Un objetivo exploratorio es evaluar la actividad de cabozantinib como agente único así como su seguridad en esta población de pacientes. |
|
E.2.2 | Secondary objectives of the trial |
Not applicable |
No aplicable |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Histological or cytological diagnosis of HCC. - The subject has disease that is not amenable to a curative treatment approach (eg, transplant, surgery, ablation therapy) or locoregional therapy (eg, TACE). - Measurable disease per RECIST 1.1 as determined by the Investigator. Barcelona Clinic Liver Cancer (BCLC) stage Category B or C. - Child-Pugh Score of A. - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. |
-Diagnóstico de CHC histológico o citológico. -La enfermedad del paciente no es susceptible a un enfoque de tratamiento curativo (como, trasplante, cirugía, ablación) o tratamiento locorregional (como TACE). -Enfermedad medible según RECIST 1.1, tal y como lo determine el investigador. -Categoría B o C de la clasificación Barcelona Clinic Liver Cancer (BCLC) (Anexo J). -Puntuación A de Child-Pugh (Anexo K). -Estado funcional del Eastern Cooperative Oncology Group (Grupo Oncológico Cooperativo de la Costa Este, ECOG) de 0 o 1. |
|
E.4 | Principal exclusion criteria |
- Fibrolamellar carcinoma, sarcomatoid HCC or mixed hepatocellular cholangiocarcinoma. - Prior systemic anticancer therapy for advanced HCC including but not limited to chemotherapy, small molecule kinase inhibitors, and ICIs. Subjects who have received local intratumoral or arterial chemotherapy are eligible. Subjects who have received any local anticancer therapy within 28 days prior to randomization are ineligible - Radiation therapy for bone metastasis within 2 weeks, any other radiation therapy within 8 weeks prior to randomization. - Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 8 weeks prior to randomization.. - Concomitant anticoagulation with oral anticoagulants |
-Carcinoma fibrolamelar, CHC sarcomatoide o colangiocarcinoma hepatocelular mixto. -Tratamiento antineoplásico sistémico anterior para CHC avanzado, como, entre otros, quimioterapia, moléculas pequeñas inhibidoras de cinasa e ICI. Son aptos los pacientes que han recibido quimioterapia arterial o intratumoral. Los pacientes que hayan recibido terapia anticancer local en los 28 dias antes a la aleatorización no son elegibles -Radioterapia para metástasis óseas en las 2 semanas previas o cualquier otra radioterapia en las 8 semanas previas a la aleatorización. -Anticoagulación concomitante con anticoagulantes orales |
|
E.5 End points |
E.5.1 | Primary end point(s) |
• Duration of Progression Free Survival (PFS) per Response Evaluable Criteria in Solid Tumors version 1.1 (RECIST 1.1), by Blinded Independent Radiology Committee (BIRC) • Duration of Overall Survival (OS) |
-Duracion de la supervivencia sin progression (SSP): según criterios evaluables de respuesta en tumors sólidos version 1.1 (RECIST 1.1) según el Comité de Radiológico Independiente Enmascarado (BIRC) -Duración de la supervivencia global (SG) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
• Duration of PFS: The primary analysis of PFS is event-driven and will be conducted after at least 241 events have been observed in the first 342 subjects that are randomized (based upon Greenwich Mean Time randomization date/time values) to the experimental (cabozantinib and atezolizumab) arm and control (sorafenib) arm. • Duration of OS: The primary analysis of OS is event-driven and will be conducted after at least 346 deaths have been observed in all subjects who are randomized to the experimental (cabozantinib plus atezolizumab) arm and control (sorafenib) arm, regardless of whether any study treatment or the correct study treatment is received. |
-Duración de SSP: Los análisis principales de SSP se basa en los acontecimientos y se llevarán a cabo después de que se hayan observado al menos 241 acontecimientos en los primeros 342 sujetos aleatorizados (según los valores de aleatorización de fecha/hora de Greenwich Mean Time) para el brazo experimental (cabozantinib y atezolizumab) y para el brazo de control (sorafenib) -Duración de SG: Los análisis principals de SG se basa en los acontecimientos y se llevarán a cabo después de que se hayan observado al menos 346 muertes en todos los pacientes aleatorizados en el brazo principal (cabozantinib y atezolizumab) y en el brazo de control (sorafenib), independientemente de si se recibe algún tratamiento del studio o el tratamiento de estudio correcto |
|
E.5.2 | Secondary end point(s) |
• Objective response rate (ORR) per RECIST 1.1 by BIRC |
Tasa de respuesta objetiva (TRO) por RECIST 1.1 según BIRC |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
ORR is defined as the proportion of subjects for whom the best overall response at the time of data cutoff is a complete response (CR) or partial response (PR) as assessed by the BIRC per RECIST 1.1, which is confirmed by a subsequent visit ≥ 28 days later. |
TRO es definida como la proporción de sujetos para quienes la major respues general en el momento del corte de datos es una respuesta complete (RC) o una respuesta parcial (RP) según lo evaluado por el BIRC por RECIST 1.1, que se confirma en una visita posterior >_28 dias después |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 3 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 10 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 91 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Argentina |
Australia |
Austria |
Belgium |
Brazil |
Canada |
China |
Colombia |
Czech Republic |
France |
Georgia |
Germany |
Hong Kong |
Hungary |
Ireland |
Israel |
Italy |
Korea, Republic of |
Mexico |
Netherlands |
New Zealand |
Philippines |
Poland |
Romania |
Russian Federation |
Singapore |
Spain |
Switzerland |
Taiwan |
Thailand |
Turkey |
Ukraine |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Study Completion by Country or by Site: At the time the Maintenance Phase is initiated, the study will be considered complete at sites and in countries where all subjects have completed post-treatment safety follow-up. |
Finalización del Estudio por país o por centro: En el momento en que se inicie la Faase de Mantenimiento, el estudio sera considerado como completado en los centros y en los países donde todos los pacientes hayan completado el seguimiento de seguridad posterior al tratamiento |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 10 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 4 |
E.8.9.2 | In all countries concerned by the trial months | 4 |
E.8.9.2 | In all countries concerned by the trial days | 0 |